DR-461 Identifying biomarkers that predict outcomes in BRAFV600E mutant colorectal cancer
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-461 Identifying biomarkers that predict outcomes in BRAFV600E mutant colorectal cancer
This project aims to understand how genetic alteration in an important cancer signalling pathway can impact treatment response and prognosis …
DR-469 Large scale characterization of the Pancreatic Ductal Adenocarcinoma microenvironment and its relation to prognosis and treatment benefit
We aim to characterize the tumor microenvironment (TME) of Pancreatic Ductal Adenocarcinoma (PDAC) using four big primary cohorts with bulk …
DR-471 Whole Genome CRISPR Screening Identifies Novel Regulators of Mismatch Repair in Lynch-like Syndrome
This project aims to uncover novel genetic regulators of mismatch repair (MMR) that may explain the molecular basis of Lynch-like …
DR-472 Identification of CN-LOH in CRC
Patients with colorectal cancer (CRC) often have major alterations in the genomic information. These mutations are traditionally assessed to occur …
DR-468 Investigating effects of cancer treatment on metastatic risk and survivorship
Patients diagnosed with aggressive breast cancers, such as triple-negative breast cancer, often require intensive chemotherapy treatments. While these treatments are …
DR-477 AURORA: Forecasting Treatment Resistance and Evolutionary Trajectories with Multi-Modal Data
AURORA discovers novel biomarkers that predict treatment resistance and guide therapy selection in metastatic cancers. Leveraging Hartwig’s pan-cancer whole-genome sequencing …
DR-434 NECTIN4 Prevalence and Prognostic Value in Metastatic Breast Cancer
NECTIN4 is a protein found on breast cancer cells, and new drugs can target it to kill the cancer. When …
DR-464 Stop-loss in cancer
This project investigates rare genetic changes called stop-loss mutations and their role in cancer. Using mutations called from genome and …
DR-459 Mutational imprints of endogenous DNA damage
DNA carries the instructions to life but is also constantly damaged, causing mutation and disease. Sunlight and cigarette smoke are …
DR-470 RADAR: Repurposing and Analysis of Drugable targets in Atypical Rare cancers
The RADAR study aims to improve outcomes for patients with rare cancers, which affect over 24,000 people annually in the …
DR-310 Clinical actionability for and heritable factors involved in glioblastoma
This project aims to use whole genome sequencing data to 1) describe the driver landscape of glioblastoma, 2) determine potential …
DR-405 Development of a Multi-Omic Test for Cancer of Unknown Primary
Cancer of unknown primary (CUP) is defined as a metastatic cancer where clinical investigations fail to identify the primary tissue …
Zolang de behandelaar niet weet waar de primaire tumor zit, heeft hij ook geen gerichte behandelmogelijkheid en kan ook geen inschatting worden gegeven hoe lang iemand nog heeft.